Colm Keane

2.8k total citations
84 papers, 1.4k citations indexed

About

Colm Keane is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Colm Keane has authored 84 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pathology and Forensic Medicine, 55 papers in Oncology and 21 papers in Immunology. Recurrent topics in Colm Keane's work include Lymphoma Diagnosis and Treatment (62 papers), Cancer Immunotherapy and Biomarkers (30 papers) and CAR-T cell therapy research (23 papers). Colm Keane is often cited by papers focused on Lymphoma Diagnosis and Treatment (62 papers), Cancer Immunotherapy and Biomarkers (30 papers) and CAR-T cell therapy research (23 papers). Colm Keane collaborates with scholars based in Australia, United States and Germany. Colm Keane's co-authors include Maher K. Gandhi, Frank Vari, Kimberley Jones, Jamie P. Nourse, Devinder Gill, Joshua W.D. Tobin, Pauline Crooks, Dipti Talaulikar, Sanjiv Jain and Erica Han and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Colm Keane

77 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Colm Keane Australia 21 778 645 586 294 204 84 1.4k
Nadine Martin‐Garcia France 21 728 0.9× 873 1.4× 679 1.2× 182 0.6× 92 0.5× 28 1.5k
Yue Lu China 20 683 0.9× 432 0.7× 436 0.7× 278 0.9× 106 0.5× 51 1.2k
Markus Kreuz Germany 19 392 0.5× 601 0.9× 180 0.3× 392 1.3× 125 0.6× 50 1.0k
Lingyan Ping China 15 426 0.5× 383 0.6× 219 0.4× 192 0.7× 41 0.2× 68 802
Sergei Syrbu United States 16 399 0.5× 544 0.8× 149 0.3× 173 0.6× 58 0.3× 66 910
Manfred Hensel Germany 21 490 0.6× 903 1.4× 517 0.9× 188 0.6× 79 0.4× 68 1.6k
Wook Youn Kim South Korea 16 403 0.5× 354 0.5× 215 0.4× 233 0.8× 164 0.8× 49 925
Monika Csóka Hungary 15 339 0.4× 229 0.4× 164 0.3× 266 0.9× 127 0.6× 57 876
Michaela Nathrath Germany 24 647 0.8× 313 0.5× 236 0.4× 689 2.3× 392 1.9× 70 1.8k

Countries citing papers authored by Colm Keane

Since Specialization
Citations

This map shows the geographic impact of Colm Keane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colm Keane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colm Keane more than expected).

Fields of papers citing papers by Colm Keane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colm Keane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colm Keane. The network helps show where Colm Keane may publish in the future.

Co-authorship network of co-authors of Colm Keane

This figure shows the co-authorship network connecting the top 25 collaborators of Colm Keane. A scholar is included among the top collaborators of Colm Keane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colm Keane. Colm Keane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loh, Zhixuan, Paul Yeh, Colm Keane, & Eliza A. Hawkes. (2025). Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies. Haematologica.
2.
Barraclough, Allison, Sze Ting Lee, Melinda Burgess, et al.. (2025). Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study. Blood Advances. 9(6). 1432–1441.
3.
Hawkes, Eliza A., Jodie Palmer, Richard Khor, et al.. (2025). T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial. Blood Advances. 9(20). 5263–5273.
4.
Timmerman, John M., David Lavie, Gareth P. Gregory, et al.. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.. Journal of Clinical Oncology. 42(16_suppl). 7055–7055. 2 indexed citations
5.
Timmerman, John M., David Lavie, Nathalie A. Johnson, et al.. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.. Journal of Clinical Oncology. 42(16_suppl). 7056–7056. 1 indexed citations
6.
McCulloch, Timothy R., Gustavo Rodrigues Rossi, Pui Yeng Lam, et al.. (2024). Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation. Nature Communications. 15(1). 9871–9871. 10 indexed citations
7.
8.
Chong, Geoffrey, Denise Lee, Anneke Grobler, et al.. (2024). First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study.. Journal of Clinical Oncology. 42(16_suppl). 7070–7070. 1 indexed citations
9.
Bednarska, Karolina, Rakin Chowdhury, Joshua W.D. Tobin, et al.. (2023). Epstein–Barr virus‐associated lymphomas decoded. British Journal of Haematology. 204(2). 415–433. 8 indexed citations
10.
Burgess, Melinda, Colm Keane, Joshua W.D. Tobin, et al.. (2022). Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia. Acta Haematologica. 146(2). 166–171. 1 indexed citations
11.
Cruz, Jazmina L. Gonzalez, Bijun Zeng, Muhammed B. Sabdia, et al.. (2021). Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers. 13(15). 3733–3733. 13 indexed citations
12.
Nath, Karthik, Soi Cheng Law, Muhammed B. Sabdia, et al.. (2021). Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances. 5(12). 2644–2649. 12 indexed citations
13.
14.
Vari, Frank, Colm Keane, Mark Hertzberg, et al.. (2018). Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 131(16). 1809–1819. 231 indexed citations
15.
Tuong, Zewen Kelvin, T Kobayashi, Megan S. F. Soon, et al.. (2017). B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. OncoImmunology. 7(2). e1393599–e1393599. 15 indexed citations
16.
Keane, Colm, Clare Gould, Kimberley Jones, et al.. (2016). The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. Clinical Cancer Research. 23(7). 1820–1828. 63 indexed citations
17.
Jones, Kimberley, Jamie P. Nourse, Colm Keane, Atul Bhatnagar, & Maher K. Gandhi. (2013). Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma. Clinical Cancer Research. 20(1). 253–264. 107 indexed citations
18.
Green, Michael R., Scott V. Bratman, Chih Long Liu, et al.. (2013). Utility Of Non-Invasive Monitoring Of Circulating Tumor DNA At Diagnosis, Interim Therapy, and Relapse Of DLBCL Using High-Throughput Sequencing Of Immunoglobulin Genes. Blood. 122(21). 4264–4264. 2 indexed citations
19.
Jones, Kimberley, Frank Vari, Colm Keane, et al.. (2012). Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. Clinical Cancer Research. 19(3). 731–742. 83 indexed citations
20.
Keane, Colm, et al.. (2012). Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Queensland's institutional digital repository (The University of Queensland). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nadine Martin‐Garcia Breakdown of academic impact, for papers by Yue Lu Breakdown of academic impact, for papers by Markus Kreuz Breakdown of academic impact, for papers by Lingyan Ping Breakdown of academic impact, for papers by Sergei Syrbu Breakdown of academic impact, for papers by Manfred Hensel Breakdown of academic impact, for papers by Wook Youn Kim Breakdown of academic impact, for papers by Monika Csóka Breakdown of academic impact, for papers by Michaela Nathrath
Rankless by CCL
2026